149,79 €
inkl. MwSt.
Sofort per Download lieferbar
  • Format: PDF

The concept of focal controlled drug delivery has been applied for treating illnesses that are localized to a certain tissue or organ. These delivery systems are applied directly to the diseased site and deliver a desired dose for an extended time period while minimizing systemic distribution of toxic drug. Controlled drug delivery systems have been focused on oral extended release formulations and on systemic delivery of small drugs and peptides. Despite the upsurge of interest in focal targeted drug delivery, there is currently no single reference text on the subject. By comparison, there…mehr

Produktbeschreibung
The concept of focal controlled drug delivery has been applied for treating illnesses that are localized to a certain tissue or organ. These delivery systems are applied directly to the diseased site and deliver a desired dose for an extended time period while minimizing systemic distribution of toxic drug. Controlled drug delivery systems have been focused on oral extended release formulations and on systemic delivery of small drugs and peptides. Despite the upsurge of interest in focal targeted drug delivery, there is currently no single reference text on the subject. By comparison, there are numerous authored and edited books on oral, systemic and transdermal drug delivery or books on biodegradable polymers as drug carriers. Thus, the aim of Focal Drug Delivery is to bring together leading experts and researchers in the field to provide an authoritative account of the essential pharmaceutical, technological, physiological and biological sciences underpinning the topic. In addition, the book will review advances in treatment options for diseases localized at a certain tissue or organ.
Autorenporträt
ABRAHAM J. DOMB is Professor for Medicinal Chemistry and Biopolymers at the Faculty of Medicine of the Hebrew University in Jerusalem, Israel. He earned bachelor’s degrees in chemistry, pharmacy and law studies and a Ph.D. in chemistry from Hebrew University. He did his postdoctoral training at MIT and Harvard University and was R&D manager at Nova Pharm in Baltimore between 1988 and 1992. His primary research interests are in biopolymers, controlled drug delivery, cancer therapy, nanoparticulate systems, and forensic sciences.

WAHID KHAN obtained his master’s degree and Ph.D. in pharmaceutics at the National Institute of Pharmaceutical & Educational Research (NIPER) in Mohali, India. He worked with Prof. Abraham J. Domb in The Hebrew University of Jerusalem, Israel, for his post-doctoral research. Currently, he is working as Assistant Professor in the Department of Pharmaceutics at NIPER in Hyderabad, India. His experience includes areas ranging from drug delivery and drug targeting to nanomedicine and biodesign of implantable medical devices.